Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 11/20 | 0.61 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 5/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | HTR2B | P41595 | 4/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 7/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3334817 | 0.92 | CHRNA4 (0.59) | CHRNA4CNR2SLC8A1HTR2CHTR2A | |
| SCHEMBL3336122 | 0.91 | CHRNA4 (0.53) | CHRNA4CNR2SLC8A1PARP1CHRNB2 | |
| SCHEMBL3336708 | 0.90 | CHRNA4 (0.55) | CHRNA4CNR2SLC8A1PARP1HTR2C | |
| SCHEMBL3332766 | 0.86 | CHRNA4 (0.68) | CHRNA4CNR2CHRNB2CHRNA7CHRNB4 | |
| SCHEMBL3334548 | 0.82 | CHRNA4 (0.58) | CHRNA4CNR2CHRNB2CHRNA7CHRNB4 | |
| SCHEMBL3336729 | 0.80 | CHRNA4 (0.49) | CHRNA4CNR2CHRNB2CHRNA7 | |
| SCHEMBL3337000 | 0.79 | CHRNA4 (0.82) | CHRNA4CHRNB2CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL3334097 | 0.78 | CHRNA4 (0.62) | CHRNA4 | |
| SCHEMBL3333566 | 0.78 | CHRNA4 (0.60) | CHRNA4CNR2CHRNB2CHRNA7CHRNB4 | |
| SCHEMBL3339757 | 0.76 | CHRNA4 (0.61) | CHRNA4SLC8A1PARP1HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | US | claimed |
| WO-2008112734-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2008112734-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | CHRNA10, CHRNA2, CHRNE | CHRNA4 8/4885CNR2 46/4885SLC8A1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.